AZD4604
Sponsors
Astrazeneca AB, AstraZeneca AB, AstraZeneca
Conditions
Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABAAsthmaHealthy Participants
Phase 1
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.
CompletedNCT06519968
Start: 2024-07-15End: 2024-12-27Updated: 2025-11-17
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma.
CompletedNCT06732882
Start: 2025-02-27End: 2025-05-29Updated: 2025-06-05
Phase 2
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
CompletedNCT06020014
Start: 2023-11-16End: 2025-10-28Updated: 2025-11-13
A Phase 2a Randomised, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate to Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
CompletedCTIS2023-506000-50-00
Start: 2024-09-26End: 2025-06-12Target: 124Updated: 2025-06-04
Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma
CompletedNCT06435273
Start: 2024-08-05End: 2025-10-15Updated: 2025-10-23
A Randomised, Double-blind, Parallel Group, Placebo Controlled,
4-Week, Phase II Study to Evaluate the Effect of AZD4604 on
Airway Inflammation and Biomarkers in Adults with Asthma - Artemisia study
CompletedCTIS2023-510291-32-00
Start: 2024-09-26End: 2025-08-13Target: 20Updated: 2025-07-02